Hydrazide compounds

Abstract

Compounds of formula (I):wherein:n is 0 or 1,W represents -CO- or S(O)r wherein r is 0, 1 or 2,Z represents a group selected from aryl, arylalkyl, heteroaryl and heteroarylalkyl, each optionally substituted,R represents a grouping selected from:Z1-T-CO-, Z1-O-T-CO-, Z1-T-O-CO-, Z1-T-S(O)q-wherein Z1, T and q are as defined in the description,A represents alkylene, alkenylene or alkynylene each having from 3 to 8 carbon atoms, alkylenecycloalkylene, cycloalkylenealkylene, alkylenecycloalkylenealkylene, alkylenearylene, arylenealkylene, alkylenearylenealkylene a groupingwhereinB1 is as defined in the description, or A forms with the adjacent nitrogen atom a groupingas defined in the description, andmedicinal products containing the same which are useful as Neuropeptide Y receptors ligands.

We claim:  
     
       1. A compound selected from those of formula (I): 
       
         
           R—NH—A—CO—NH—NH—(W) n —Z  (I)  
         
       
       wherein: 
       n is 0 or 1,  
       W represents —CO— or S(O) r  wherein r is 0, 1 or 2,  
       Z represents a group selected from optionally substituted aryl and optionally substituted arylalkyl,  
       R represents a group selected from:  
       Z 1 —T—CO— 
       Z 1 —O—T—CO— 
       Z 1 —T—O—CO— 
       Z 1 —T—S(O) q — 
       wherein: 
       Z 1  represents optionally substituted aryl or optionally substituted arylalkyl,  
       T represents a σ bond, alkylene, alkenylene, or alkynylene,  
       q represents an 0, 1 or 2,  
       A represents alkylenecycloalkylene, cycloalkylenealkylene, alkylenecycloalkylenealkylene, alkylenearylene, arylenealkylene, alkylenearylenealkylene,                    
       wherein B 1  represents optionally substituted aryl or optionally substituted arylalkyl, with the proviso that when simultaneously n is 0, A represents                    
       B 1  being benzyl, and Z represents optionally substituted phenyl, then R is other than benzoyl, its enantiomers, diastereoisomers, and pharmaceutically-acceptable an addition salts thereof with an pharmaceutically-acid or base, it being understood that: 
       the term “alkyl” denotes a linear or branched alkyl group having 1 to 6 carbon atoms,  
       the term “alkylene” denotes a linear or branched bivalent alkylene radical containing from 1 to 6 carbon atoms, unless indicated otherwise,  
       the term “alkenylene” denotes a linear or branched bivalent alkylene radical containing 2 to 6 carbon atoms and 1 to 3 double bonds, unless indicated otherwise,  
       the term “alkynylene” denotes a linear or branched alkylene bivalent radical containing 2 to 6 carbon atoms and 1 to 3 triple bonds, unless indicated otherwise,  
       the term “aryl” denotes phenyl, naphthyl, dihydronaphthyl or tetrahydronaphthyl, and the term “arylene” denotes a bivalent radical of the same type,  
       the term “alkylenecycloalkylene” represents —A 1 —A 2 —, the term “cycloalkylene-alkylene” represents —A 2 —A 1 —, and the term “alkylenecycloalllylenealkylene” represents —A 1 —A 2 —A 1 , the term “alkylenearylene” represents —A 1 —A 3 —, the term “arylenealkylene” represents —A 3 —A 1 —, the term “alkylenearylenealkylene” represents —A 1 —A 3 —A 1 —, wherein A 1  is alkylene as defined hereinbefore, A 2  is (C 4 -C 8 )cycloalkylene, and A 3  is arylene as defined hereinbefore,  
       the expression “optionally substituted” applied to the terms “aryl” or, “arylalkyl”, indicates that those groups maybe substituted on their cyclic moiety by 1 to 5 identical or different substituents selected from linear or branched (C 1 -C 6 )alkyl, linear or branched (C 1 -C 6 )alkoxy, halogen, hydroxy, perhalo-(C 1 -C 6 )alkyl in which the alkyl moiety is linear or branched, nitro, linear or branched (C 1 -C 6 )acyl, linear or branched (C 1 -C 6 )alkylsulphonyl, and amino (amino being optionally substituted by one or two linear or branched (C 1 -C 6 )alkyl and/or linear or branched (C 1 -C 6 )acyl).  
     
     
       2. A compound of claim  1  wherein W represents —CO—. 
     
     
       3. A compound of claim  1  wherein W represents —SO 2 —. 
     
     
       4. A compound of claim  1  wherein R represents Z 1 —T—CO, T being alkylene or a bond. 
     
     
       5. A compound of claim  1  wherein R represents Z 1 —O—T—CO, T being alkylene or a bond. 
     
     
       6. A compound of claim  1  wherein R represents Z 1 —T—O—CO, T being alkylene or a bond. 
     
     
       7. A compound of claim  1  wherein R represents Z 1 —T—S(O) q —, T being alkylene or a bond. 
     
     
       8. A Compound of claim  1  wherein Z represents an optionally substituted aryl, its enantiomers, diastereoisomers, and addition salts thereof with a pharmaceutically-acceptable acid or base. 
     
     
       9. A compound of claim  1  wherein A represents                    
       wherein B 1  is optionally substituted arylalkyl. 
     
     
       10. A compound of claim  1  wherein A represents alkylenecycloalkylene. 
     
     
       11. A compound of claim  1  wherein A represents alkylenearylene. 
     
     
       12. A compound of claim  1  selected from those wherein W represents —CO—, Z represents a group selected from optionally substituted aryl, R represents a grouping selected from Z 1 —T—CO—, Z 1 —O—T—CO—, Z 1 —T—O—CO—, and Z 1 —T—S(O) q —, wherein Z 1  is optionally substituted aryl, T represents alkylene, and q is 2, and A represents alkylenecycloalkylene,                    
       wherein B 1  is optionally substituted arylalkyl, and its enantiomers, diastereoisomers, and addition salts thereof with a pharmaceutically-acceptable acid or base. 
     
     
       13. A compound of claim  1  which is selected from N2-({4-[(2-benzoylhydrazino)-carbonyl]cyclohexyl}methyl)-2-naphthalenesulphonamide, and its enantiomers, diastereoisomers, and addition salts thereof with a pharmaceutically-acceptable acid or base. 
     
     
       14. A compound of claim  1  which is selected from N1-({4-[(2-benzoylhydrazino)-carbonyl]cyclohexyl}methyl)-1-(2-nitrobenzene)sulphonamide, and its enantiomers, diastereoisomers, and addition salts thereof with a pharmaceutically-acceptable acid or base. 
     
     
       15. A compound of claim  1  which is selected from N1-[1-benzyl-2-oxo-2-(2-phenylhydrazino)ethyl]-1-(4-chlorobenzene)sulphonamide, and addition salts thereof with a pharmaceutically-acceptable acid or base. 
     
     
       16. A pharmaceutical composition useful as a Neuropeptide Y receptor ligand comprising as active principle an effective amount of a compound as claimed in claim  1 , together with with one or more pharmaceutically-acceptable excipients or vehicles. 
     
     
       17. A method for treating a living animal body afflicted with a condition requiring a neuropeptide Y receptor ligand and associated with eating behaviour disorders and/or energy balance disorders selected from diabetes, obesity, bulimia, and anorexia nervosa, comprising the step of administering to the living body an amount of a compound of claim  1  which is effective for alleviation of said condition. 
     
     
       18. A method for treating a living animal body afflicted with a condition requiring a neuropeptide Y receptor ligand and selected from arterial hypertension, anxiety, depression, epilepsy, sexual dysfunctions and sleep disorders, comprising the step of administering to the living body an amount of a compound of claim  1  which is effective for alleviation of said condition.